Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 12/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.52 |
| ▸ | ELANE | P08246 | 2/20 | 0.51 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | TMPRSS15 | P98073 | 6/20 | 0.48 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27274105 | 0.86 | PARP10 (0.59) | ELANE | |
| SCHEMBL23493150 | 0.85 | ELANE (0.55) | ELANE | |
| SCHEMBL15679080 | 0.85 | ELANE (0.55) | ELANE | |
| Hydrochloric Acid SCHEMBL30184762 | 0.83 | ELANE (0.53) | ELANE | |
| SCHEMBL364405 | 0.82 | KMT2A (0.56) | ELANE | |
| SCHEMBL8681157 | 0.82 | ELANE (0.55) | PRSS1ELANE | |
| SCHEMBL1061790 | 0.82 | ELANE (0.55) | ELANE | |
| SCHEMBL7870131 | 0.82 | ELANE (0.55) | PRSS1ELANE | |
| SCHEMBL4144843 | 0.81 | PRSS1 (0.57) | PRSS1PRSS2PRSS3F2PLAU | |
| SCHEMBL237660 | 0.79 | GLA (0.47) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374707-A1 | EXPRESSION SYSTEM AND NUCLEIC ACID-BASED PHARMACEUTICAL COMPOSITION COMPRISING SAME | SML BIOPHARM CO, LTD. (KR) | 2024-11-14 | — | — | US | disclosed |
| EP-4450628-A1 | NUCLEIC ACID EXPRESSION PLATFORM WITH INCREASED EXPRESSION EFFICIENCY | SML Biopharm Co., Ltd. (KR) | 2024-10-23 | — | — | EP | disclosed |
| US-9943567-B2 | Method for treating arthritis using IK factor or nucleic acid encoding IK factor | Catholic University Industry Academic Cooperation Foundation (KR) | 2018-04-17 | — | — | US | disclosed |
| US-9737588-B2 | Method for treating arthritis using IK factor or nucleic acid encoding IK factor | CELLINBIO CO., LTD (KR) | 2017-08-22 | — | — | US | disclosed |
| US-20170209541-A1 | METHOD FOR TREATING ARTHRITIS USING IK FACTOR OR NUCLEIC ACID ENCODING IK FACTOR | CELLINBIO CO., LTD. (KR) | 2017-07-27 | — | — | US | disclosed |
| US-20160376449-A1 | ANTIFOULING MATERIALS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-12-29 | — | — | US | disclosed |
| US-20160058836-A1 | IK FACTOR AND PHARMACEUTICAL USE OF NUCLEIC ACID ENCODING IK FACTOR | CELLINBIO CO., LTD (KR) | 2016-03-03 | — | — | US | disclosed |
| US-7407982-B2 | Oligo or polyalkylene glycol-coupled thrombin inhibitors | HAEMOSYS GMBH (DE) | 2008-08-05 | — | — | US | disclosed |
| US-20050070479-A1 | Oligo or polyalkylene glycol-coupled thrombin inhibitors | HAEMOSYS GMBH (DE) | 2005-03-31 | — | — | US | disclosed |
| EP-0833839-B1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMA CORP (US) | 2003-01-08 | — | — | EP | disclosed |
| US-5827860-A | Peptidyl heterocycles useful in the treatment of thrombin related disorders | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-10-27 | — | — | US | disclosed |
| US-5827866-A | ANTICOAGULANTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-10-27 | — | — | US | disclosed |
| EP-0833839-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996040741-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040742-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATEDDISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040748-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5523308-A | SERINE PROTEASES INHIBITORS; ORAL ANTICOAGULANTS; CHEMICAL INTERMEDIATES; DIPEPTIDES | ORTHO PHARMACEUTICAL CORPORATION | 1996-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376449-A1 | ANTIFOULING MATERIALS | PFAS, FLNB, FLNA | PRSS1 4561/4885PRSS2 4686/4885PRSS3 4393/4885 |
| US-20050070479-A1 | Oligo or polyalkylene glycol-coupled thrombin inhibitors | TFPI, SERPINC1, PLG | PRSS1 20/4885PRSS2 41/4885PRSS3 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.